- Home
- GIGM vs CTXR Comparison
GIGM vs CTXR Comparison
Compare GIGM & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- CTXR
- Stock Information
- Founded
- GIGM 1998
- CTXR 2007
- Country
- GIGM Taiwan
- CTXR United States
- Employees
- GIGM N/A
- CTXR N/A
- Industry
- GIGM Computer Software: Programming Data Processing
- CTXR Biotechnology: Pharmaceutical Preparations
- Sector
- GIGM Technology
- CTXR Health Care
- Exchange
- GIGM Nasdaq
- CTXR Nasdaq
- Market Cap
- GIGM 20.2M
- CTXR 22.6M
- IPO Year
- GIGM 2000
- CTXR N/A
- Fundamental
- Price
- GIGM $1.64
- CTXR $1.40
- Analyst Decision
- GIGM
- CTXR Strong Buy
- Analyst Count
- GIGM 0
- CTXR 3
- Target Price
- GIGM N/A
- CTXR $53.00
- AVG Volume (30 Days)
- GIGM 21.7K
- CTXR 376.3K
- Earning Date
- GIGM 10-29-2025
- CTXR 08-12-2025
- Dividend Yield
- GIGM N/A
- CTXR N/A
- EPS Growth
- GIGM N/A
- CTXR N/A
- EPS
- GIGM N/A
- CTXR N/A
- Revenue
- GIGM $3,250,000.00
- CTXR N/A
- Revenue This Year
- GIGM N/A
- CTXR N/A
- Revenue Next Year
- GIGM N/A
- CTXR $851.67
- P/E Ratio
- GIGM N/A
- CTXR N/A
- Revenue Growth
- GIGM N/A
- CTXR N/A
- 52 Week Low
- GIGM $1.33
- CTXR $0.65
- 52 Week High
- GIGM $1.89
- CTXR $12.84
- Technical
- Relative Strength Index (RSI)
- GIGM 45.38
- CTXR 62.51
- Support Level
- GIGM $1.57
- CTXR $1.11
- Resistance Level
- GIGM $1.72
- CTXR $1.40
- Average True Range (ATR)
- GIGM 0.07
- CTXR 0.07
- MACD
- GIGM -0.03
- CTXR 0.03
- Stochastic Oscillator
- GIGM 24.01
- CTXR 70.75
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.